141 related articles for article (PubMed ID: 29551446)
1. Impact of HIV Infection on Transplant Outcomes after Autologous Peripheral Blood Stem Cell Transplantation: A Retrospective Study of Japanese Registry Data.
Yoshinaga N; Kanda J; Aisa Y; Hagiwara S; Mori T; Fukuda T; Ishida Y; Hashimoto H; Iwato K; Kanda Y; Kurokawa M; Nakazawa H; Ota S; Uchida N; Ichinohe T; Atsuta Y; Takaori-Kondo A
Biol Blood Marrow Transplant; 2018 Aug; 24(8):1596-1601. PubMed ID: 29551446
[TBL] [Abstract][Full Text] [Related]
2. Cytomegalovirus reactivation in lymphoma and myeloma patients undergoing autologous peripheral blood stem cell transplantation.
Massoud R; Assi R; Fares E; Haffar B; Charafeddine M; Kreidieh N; Mahfouz R; Kanj SS; El Zakhem A; Kharfan-Dabaja M; Bazarbachi A; El Cheikh J
J Clin Virol; 2017 Oct; 95():36-41. PubMed ID: 28843110
[TBL] [Abstract][Full Text] [Related]
3. HIV status does not affect the outcome of autologous stem cell transplantation (ASCT) for non-Hodgkin lymphoma (NHL).
Krishnan A; Palmer JM; Zaia JA; Tsai NC; Alvarnas J; Forman SJ
Biol Blood Marrow Transplant; 2010 Sep; 16(9):1302-8. PubMed ID: 20353830
[TBL] [Abstract][Full Text] [Related]
4. Mortality patterns among recipients of autologous hematopoietic stem cell transplantation for lymphoma and myeloma in the past three decades.
Bhatt VR; Loberiza FR; Jing H; Bociek RG; Bierman PJ; Maness LJ; Vose JM; Armitage JO; Akhtari M
Clin Lymphoma Myeloma Leuk; 2015 Jul; 15(7):409-415.e1. PubMed ID: 25816932
[TBL] [Abstract][Full Text] [Related]
5. High dose therapy and autologous stem cell transplantation for human immunodeficiency virus-associated non-Hodgkin lymphoma in the era of highly active antiretroviral therapy.
Molina A; Krishnan AY; Nademanee A; Zabner R; Sniecinski I; Zaia J; Forman SJ
Cancer; 2000 Aug; 89(3):680-9. PubMed ID: 10931469
[TBL] [Abstract][Full Text] [Related]
6. Hematopoietic Cell Transplantation-Specific Comorbidity Index Predicts Morbidity and Mortality in Autologous Stem Cell Transplantation.
Berro M; Arbelbide JA; Rivas MM; Basquiera AL; Ferini G; Vitriu A; Foncuberta C; Fernandez Escobar N; Requejo A; Milovic V; Yantorno S; Szelagoswki M; Martinez Rolon J; Bentolila G; Garcia JJ; Garcia P; Caeiro G; Castro M; Jaimovich G; Palmer S; Trucco JI; Bet LA; Shaw BE; Kusminsky GD
Biol Blood Marrow Transplant; 2017 Oct; 23(10):1646-1650. PubMed ID: 28669923
[TBL] [Abstract][Full Text] [Related]
7. Cardiovascular toxicity is increased, but manageable, during high-dose chemotherapy and autologous peripheral blood stem cell transplantation for patients aged 60 years and older.
Mileshkin LR; Seymour JF; Wolf MM; Gates P; Januszewicz EH; Joyce P; Prince HM
Leuk Lymphoma; 2005 Nov; 46(11):1575-9. PubMed ID: 16236612
[TBL] [Abstract][Full Text] [Related]
8. A national study on conditional survival, excess mortality and second cancer after high dose therapy with autologous stem cell transplantation for non-Hodgkin lymphoma.
Smeland KB; Kiserud CE; Lauritzsen GF; Blystad AK; Fagerli UM; Falk RS; Fluge Ø; Fosså A; Kolstad A; Loge JH; Maisenhölder M; Østenstad B; Kvaløy S; Holte H
Br J Haematol; 2016 May; 173(3):432-43. PubMed ID: 26914167
[TBL] [Abstract][Full Text] [Related]
9. Peripheral-blood stem-cell transplantation versus autologous bone marrow transplantation in Hodgkin's and non-Hodgkin's lymphomas: a new matched-pair analysis of the European Group for Blood and Marrow Transplantation Registry Data. Lymphoma Working Party of the European Group for Blood and Marrow Transplantation.
Majolino I; Pearce R; Taghipour G; Goldstone AH
J Clin Oncol; 1997 Feb; 15(2):509-17. PubMed ID: 9053472
[TBL] [Abstract][Full Text] [Related]
10. Early lymphocyte recovery predicts superior survival after autologous hematopoietic stem cell transplantation in multiple myeloma or non-Hodgkin lymphoma.
Porrata LF; Gertz MA; Inwards DJ; Litzow MR; Lacy MQ; Tefferi A; Gastineau DA; Dispenzieri A; Ansell SM; Micallef IN; Geyer SM; Markovic SN
Blood; 2001 Aug; 98(3):579-85. PubMed ID: 11468153
[TBL] [Abstract][Full Text] [Related]
11. Late non-relapse mortality among adult autologous stem cell transplant recipients: a nation-wide analysis of 1,482 patients transplanted in 1990-2003.
Jantunen E; Itälä M; Siitonen T; Koivunen E; Leppä S; Juvonen E; Kuittinen O; Lehtinen T; Koistinen P; Nyman H; Nousiainen T; Volin L; Remes K
Eur J Haematol; 2006 Aug; 77(2):114-9. PubMed ID: 16856906
[TBL] [Abstract][Full Text] [Related]
12. Second autologous transplantation after failure of a first autologous transplant in 18 patients with non-Hodgkin's lymphoma.
Lenain C; Dumontet C; Gargi T; Chassagne C; Berger F; Perol D; Garnier M; Coiffier B; Blay JY
Hematol J; 2004; 5(5):403-9. PubMed ID: 15448666
[TBL] [Abstract][Full Text] [Related]
13. Complete remission status before autologous stem cell transplantation is an important prognostic factor in patients with multiple myeloma undergoing upfront single autologous transplantation.
Kim JS; Kim K; Cheong JW; Min YH; Suh C; Kim H; Jo DY; Ryoo HM; Yoon SS; Lee JH;
Biol Blood Marrow Transplant; 2009 Apr; 15(4):463-70. PubMed ID: 19285634
[TBL] [Abstract][Full Text] [Related]
14. Autologous stem cell transplantation in multiple myeloma: Post-transplant outcomes of Taiwan Blood and Marrow Transplantation Registry.
Huang TC; Huang SY; Yao M; Lin CY; Hwang WL; Gau JP; Tan TD; Wang PN; Liu YC; Lin SC; Kao RH; Pei SN; Yu MS; Lin HY; Su YC; Chen CC; Li SS; Wu YY
J Formos Med Assoc; 2019 Jan; 118(1 Pt 3):471-480. PubMed ID: 30119948
[TBL] [Abstract][Full Text] [Related]
15. Outcome after autologous and allogeneic stem cell transplantation for patients with multiple myeloma: impact of graft-versus-myeloma effect.
Alyea E; Weller E; Schlossman R; Canning C; Mauch P; Ng A; Fisher D; Gribben J; Freeman A; Parikh B; Richardson P; Soiffer R; Ritz J; Anderson KC
Bone Marrow Transplant; 2003 Dec; 32(12):1145-51. PubMed ID: 14647268
[TBL] [Abstract][Full Text] [Related]
16. Autologous stem cell transplantation in first remission is associated with better progression-free survival in multiple myeloma.
Aggarwal M; Agrawal N; Yadav N; Verma P; Ahmed R; Mehta P; Kapoor J; Bhurani D
Ann Hematol; 2018 Oct; 97(10):1869-1877. PubMed ID: 29781040
[TBL] [Abstract][Full Text] [Related]
17. Bacteremias following autologous stem cell transplantation for multiple myeloma: Risk factors and outcomes.
Mohan M; Susanibar-Adaniya S; Buros A; Crescencio JCR; Burgess MJ; Lusardi K; Davies F; Morgan G; Vanrhee F; Zangari M; Schinke C; Thanendrarajan S; Kothari A
Transpl Infect Dis; 2019 Apr; 21(2):e13052. PubMed ID: 30689291
[TBL] [Abstract][Full Text] [Related]
18. Higher infused lymphocyte dose predicts higher lymphocyte recovery, which in turn, predicts superior overall survival following autologous hematopoietic stem cell transplantation for multiple myeloma.
Hiwase DK; Hiwase S; Bailey M; Bollard G; Schwarer AP
Biol Blood Marrow Transplant; 2008 Jan; 14(1):116-24. PubMed ID: 18158968
[TBL] [Abstract][Full Text] [Related]
19. Superior survival after replacing oral with intravenous busulfan in autologous stem cell transplantation for non-Hodgkin lymphoma with busulfan, cyclophosphamide and etoposide.
Dean RM; Pohlman B; Sweetenham JW; Sobecks RM; Kalaycio ME; Smith SD; Copelan EA; Andresen S; Rybicki LA; Curtis J; Bolwell BJ
Br J Haematol; 2010 Jan; 148(2):226-34. PubMed ID: 19821828
[TBL] [Abstract][Full Text] [Related]
20. Comorbidities, not age, impact outcomes in autologous stem cell transplant for relapsed non-Hodgkin lymphoma.
Wildes TM; Augustin KM; Sempek D; Zhang QJ; Vij R; Dipersio JF; Devine SM
Biol Blood Marrow Transplant; 2008 Jul; 14(7):840-6. PubMed ID: 18541205
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
